MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

ABSTRACT:

Background

Non-small cell lung cancers (NSCLCs) harboring specific genetic alterations can be highly sensitive to targeted therapies.

Materials and methods

We performed a targeted rearrangement assay on 54 NSCLCs across all stages that were from patients who were never smokers and did not have driver mutations. Because MET exon 14 skipping was the most frequent alteration found, we surveyed the results for MET exon 14 skipping at Massachusetts General Hospital (MGH) since the inclusion of this alteration into our current molecular profiling panel.

Results

In a cohort of 54 never-smokers with lung cancers that were wild-type for known driver mutations, MET exon 14 skipping was the most frequently recurring alteration, occurring in 10 cancers (19%). Clinical testing at

SUBMITTER: Heist RS 

PROVIDER: S-EPMC4828128 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature